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Proteomics-Based Metabolic Modeling Reveals
That Fatty Acid Oxidation (FAO) Controls
Endothelial Cell (EC) Permeability*□S
Francesca Patella‡, Zachary T. Schug§, Erez Persi¶, Lisa J. Neilson‡, Zahra Erami**,
Daniele Avanzato‡‡, Federica Maione§§¶¶, Juan R. Hernandez-Fernaud‡,
Gillian Mackay§, Liang Zheng§, Steven Reid‡, Christian Frezza, Enrico Giraudo§§¶¶,
Alessandra Fiorio Pla‡‡, Kurt Anderson**, Eytan Ruppin¶a, Eyal Gottlieb§,
and Sara Zanivan‡b
Endothelial cells (ECs) play a key role to maintain the
functionality of blood vessels. Altered EC permeability
causes severe impairment in vessel stability and is a hall-
mark of pathologies such as cancer and thrombosis. In-
tegrating label-free quantitative proteomics data into ge-
nome-wide metabolic modeling, we built up a model that
predicts the metabolic fluxes in ECs when cultured on a
tridimensional matrix and organize into a vascular-like
network. We discovered how fatty acid oxidation in-
creases when ECs are assembled into a fully formed net-
work that can be disrupted by inhibiting CPT1A, the fatty
acid oxidation rate-limiting enzyme. Acute CPT1A inhibi-
tion reduces cellular ATP levels and oxygen consumption,
which are restored by replenishing the tricarboxylic acid
cycle. Remarkably, global phosphoproteomic changes
measured upon acute CPT1A inhibition pinpointed altered
calcium signaling. Indeed, CPT1A inhibition increases intra-
cellular calcium oscillations. Finally, inhibiting CPT1A in-
duces hyperpermeability in vitro and leakage of blood ves-
sel in vivo, which were restored blocking calcium influx or
replenishing the tricarboxylic acid cycle. Fatty acid oxida-
tion emerges as central regulator of endothelial functions
and blood vessel stability and druggable pathway to control
pathological vascular permeability. Molecular & Cellular
Proteomics 14: 10.1074/mcp.M114.045575, 621–634, 2015.
Endothelial cells (ECs)1 line the inner layer of the blood
vessel wall and constitute a barrier between blood and sur-
rounding tissue. As such, a tight regulation of EC permeability
is crucial to maintain vessel functionality and avoid excessive
extravasation of fluid and plasma proteins (1). Increased en-
dothelial permeability is typical in inflammatory states and a
hallmark of diseases such thrombosis, atherosclerosis, and
cancer (2, 3). Because of their unique localization, ECs are
constantly exposed to oxygen and nutrients that fuel cell
metabolism and whose levels vary in physiological and path-
ological conditions. Yet, how cell metabolism regulates endo-
thelial permeability remains incompletely understood.
Previous studies have reported that EC cultures use glu-
cose as predominant source of energy by producing lactate
through glycolysis. However, also fatty acids and glutamine
contribute to ATP and metabolic intermediate production (4–
7). Recent in vivo studies have shown that glycolysis is nec-
essary for EC proliferation and motility in physiological and
pathological angiogenesis (4, 8). Moreover, the peroxisome
proliferator-activated receptor gamma coactivator 1-, which
can activate oxidative phosphorylation, blocks EC sprouting
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in diabetes (9). The intriguing information emerging from these
studies is that key metabolic pathways, such as glycolysis
and oxidative phosphorylation in the mitochondria, play an
important role in ECs and that they are actively involved in the
regulation of key cell functions.
Mitochondrial fatty acid oxidation (FAO) is the process that
converts fatty acids (FAs) into acetyl-CoA, which fuels the
tricarboxylic acid cycle (TCAc) and generates reducing factors
for producing ATP via oxidative phosphorylation. Cells can
incorporate FAs from the culture media or can generate FAs
from the hydrolysis of triglycerides or through de novo syn-
thesis. FAs, then, can access the mitochondria according to
their length; whereas short and medium-chain FAs (up to 12
carbon atoms) diffuse through the mitochondrial membrane,
long-chain FAs (with 13–21 carbon atoms) are actively trans-
ported by the carnitine O-palmitoyl transferase (CPT) proteins,
which are rate-limiting enzymes for this pathway (10). Previ-
ous work suggested that FAO is poorly utilized by EC cultures
(4), however, under certain stress conditions such as glucose
deprivation, FAO becomes a major source of energy (7). Al-
though it is striking to note how cells can adapt and remodel
their metabolism, the role of key FAO enzymes in the control
of EC functions is still largely unclear.
Because of the complexity of the cell metabolome, global-
scale metabolomic studies for in depth and quantitative
analysis of metabolic fluxes are still challenging and compu-
tational models have provided invaluable help to better un-
derstand cell metabolism. Among them, the integrative met-
abolic analysis tool (iMAT), which integrates gene expression
data with genome-scale metabolic network model (GSMM),
has been successfully used to predict enzyme metabolic flux
in several model systems and diseases (11, 12). Because
gene expression and protein levels do not always correlate,
and because enzymes levels do not necessarily reflect their
enzymatic activity or the flux of the reaction that they are
involved in, iMAT uses expression data as cue for the likeli-
hood, but not final determinant, of enzyme activity. Modern
MS technology and robust approaches for protein quantifica-
tion, such as stable-isotope labeling with amino acids in cell
culture (SILAC) (13) and advanced label-free algorithms (14),
allow global comparative proteomic analysis and accurate
measurements of protein and post-translational modification
levels (15). We reasoned that the integration of quantitative
MS-proteomic data into GSMM could contribute to the study
of cell metabolism. Moreover, metabolic changes trigger ac-
tivation of protein kinases (16, 17) to rapidly remodel the
intracellular signaling and enable cells to adapt to these sud-
den alterations. Protein phosphorylation therefore plays an
important role in regulating cell response to metabolic alter-
ation and may hide information on cellular pathways and
functions controlled by specific metabolic activities. MS-
based proteomic approaches therefore offer an additional
opportunity to investigate in an unbiased manner the interplay
between cell metabolism and cell function (18).
We have previously shown (19) that when human primary
ECs are cultured for 1 day on the three-dimensional matrix
matrigel and assemble into a complex network, a simplified
model that recapitulates some aspects of vascular network
assembly in vivo (20), the levels of metabolic enzymes are
profoundly regulated. This result suggested an interplay be-
tween cell metabolism and EC behavior. Here we investigate
further this aspect. Integrating label-free quantitative MS-pro-
teomics, predictive metabolic modeling and metabolomics
we discovered increased FAO when ECs are assembled into
a fully formed network. Moreover, by inhibiting CPT1 pharma-
cologically, we elucidated that FAO is a central regulator of EC
permeability in vitro and blood vessel stability in vivo. Thus,
proteomics significantly contributes to the study of cell me-
tabolism and here we identified FAO as a promising target for
therapeutic intervention for the control of pathological vascu-
lar permeability.
EXPERIMENTAL PROCEDURES
Cells, Reagents, and Treatments—Human umbilical vein endothe-
lial cells (HUVECs) isolated from 2–5 umbilical cords were pooled and
cultured in EGM-2 (Lonza, Basel, Switzerland). For the SILAC label-
ing, cells were grown for three passages (P) in custom EGM-2 without
arginine and lysine (Lonza) supplemented with L-arginine and L-lysine
(SILAC light) (Sigma-Aldrich, St. Louis, MO), 13C6 L-arginine and D4
L-lysine (SILAC medium) or 13C6
15N4 L-arginine, and
13C6
15N2 L-lysine
(SILAC heavy) (Cambridge Isotope Laboratories, Tewksbury, MA).
BOECs were kindly provided by Dr. Maartje van den Biggelaar and
cultured in EGM-2 medium 10% FBS. Cells were used between P2
and P6.
If not otherwise stated, after 2 h etomoxir treatment (15 g/ml)
cells were treated or not with pyruvate (500 M) for 30 min followed
by dichloroacetate (5 mM) for 30 min before cells were used in
experiments.
Etomoxir, oxfenicine, dichloroacetate, pyruvate, thrombin, VEGF,
and mouse anti-vinculin antibody were from Sigma-Aldrich; anti-
CPT1A antibody (15184–1-AP) was from Protein Tech group (Chi-
cago, IL); anti--tubulin was from Santa Cruz Biotechnology (Dallas,
TX), anti-phospho ACACA was from Cell Signaling (Danvers, MA);
anti-mouse IRDye 700CW, and anti-rabbit IRDye 800CW used for
Western blot were from LI-COR Biosciences (Lincoln, NE). Matrigel
and Cell recovery solution were from BD biosciences (Franklin Lakes,
NJ).
Matrigel Assay—HUVECs were seeded and cultured on solidified
Matrigel in EGM-2 medium with the indicated stimuli and harvested
for MS analysis using Cell recovery solution according to manufac-
turer’s instructions and as previously described (19). Pictures were
taken with Axiovert microscope and the tubule length measured with
ImageJ software.
Sample Preparation for Proteomic Analysis—HUVECs were lysed
in 2% SDS and 100 mM Tris-HCl pH 7.4 buffer.
Proteome Matrigel—Proteins were precipitated and solubilized in
8 M urea, 75 mM NaCl and 50 mM TrisHCl. After reduction with
dithiothreitol and alkylation with iodoacetamide, proteins were di-
gested with trypsin. Proteome etomoxir: Light, medium, and heavy
SILAC-labeled cell lysates (70 g/sample) were mixed in equal
amount, trypsin digested by filter-aided sample preparation (FASP)
method (22) and 50 g of peptides fractionated into six fractions
using on-tip strong anion exchange chromatography (21).
Phosphoproteome—Light, medium, and heavy SILAC-labeled cell
lysates (3 mg/sample) were mixed in equal amount, digested using
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FASP and peptides were fractionated using strong cation exchange
chromatography followed by titanium dioxide enrichment (23) for
phosphorylated peptides as previously described (24).
Digested peptides were de-salted with Empore-C18 StageTips (25),
eluted in 80% acetonitrile (ACN), 0.5% acetic acid, and stored at
80 °C until MS analysis.
Proteomic MS Analysis—Tryptic peptides were separated on 20
cm fused silica emitter (New Objective, Woburn, MA) packed in-
house with the reverse phase ReproSil-Pur C18-AQ, 1.9 m resin (Dr.
Maisch, GmbH, Ammerbuch-Entringen, Germany) and analyzed on a
LTQ-Orbitrap Elite (Thermo Fisher Scientific) coupled on-line with a
nano-HPLC (Easy nLC, Thermo Fisher Scientific).
Proteome Matrigel—For each sample, 2 g of digested peptides
were eluted from reverse phase column with a flow of 200 nl/min in
190 min gradient, from 5% to 30% ACN in 0.5% acetic acid. For each
time point three replicates were performed and each replicate was run
at the MS twice.
Proteome Etomoxir—For each fraction, half of the peptides were
loaded onto reverse phase column and eluted with a flow of 200
nl/min in 190 min gradient, from 5% to 30% ACN in 0.5% acetic acid.
Triplicate experiments were performed swapping SILAC labeling
conditions.
Phosphoproteome—For each experiment, 10 fractions enriched for
phosphorylated peptides were analyzed at the MS. Two thirds of each
sample was loaded onto reverse phase column and eluted with a flow
of 200 nl/min in 90 min gradient, from 5% to 30% ACN in 0.5% acetic
acid. The remaining 1/3 was pooled into two fractions that were
analyzed at the MS. Triplicate experiments were performed swapping
SILAC labeling conditions.
MS spectra were acquired in the Orbitrap analyzer at a resolution of
120,000 at 400 m/z, and a target value of 106 charges. High collision
dissociation fragmentation of the 10 most intense ions was performed
using a target value of 40,000 charges and acquired in the Orbitrap at
resolution 15,000 at 400 m/z. Data were acquired with Xcalibur soft-
ware. MS data were processed using the MaxQuant software (26) and
searched with Andromeda search engine (27) against the human
UniProt database (release-2012 01, 81,213 entries). An initial maximal
mass deviation of 7 ppm and 20 ppm was required to search for
precursor and fragment ions, respectively. Trypsin with full enzyme
specificity and peptides with a minimum length of seven amino acids
were selected. Two missed cleavages were allowed. Oxidation (Met)
and N-acetylation were set as variable modifications, as well as
phospho(STY) for the phosphoproteome analysis, whereas Carbam-
idomethylation (Cys) as fixed modification. False discovery rate (FDR)
of 1% was used for peptides, proteins and phosphopeptides identi-
fication. For the phosphosites, a minimum Andromeda phosphopep-
tides score of 40 was required, as previously described (28).
Proteomic Data Analysis—
Proteome Matrigel—Peptides and proteins were quantified accor-
ding to the MaxLFQ algorithm of MaxQuant (14) version 1.4.1.0. Only
proteins uniquely identified with minimum one unique peptide and
quantified in at least three MS runs were used for the analysis.
Proteome Etomoxir—The relative quantification of the proteins
against their labeled counterpart was performed by MaxQuant (14)
version 1.5.0.36. Only proteins identified with minimum one unique
peptide and quantified with a minimum of two ratio counts were used
for the analysis. Proteins were considered up-regulated if the SILAC
ratio was higher than 0.3 (log2 scale), which was more than one
standard deviation from the mean of the all calculated ratios, in a
minimum of two replicates.
Phosphoproteome—The relative quantification of the phosphory-
lation sites against their labeled counterpart was performed by Max-
Quant (14) version 1.4.1.6. Only class I sites ( sites accurately
localized with localization probability 0.75 and score difference 5)
were used for the analysis. Phosphorylation sites were considered
up-regulated if the SILAC ratio was higher than 0.4 (log2 scale), which
was more than one standard deviation from the mean of the all
calculated ratios, in a minimum of two replicates. For the NetworKIN
analysis (29), for each phosphorylation site only the predicted kinase
with highest score was considered and we required a minimum
NetworKIN score of 1.5. Motif-X analysis was performed using stan-
dard parameters, significance of 0.000001 and IPI Human Proteome
as background (30). Predicted kinase activity was calculated by
means of significantly overrepresented (Fisher test, with 2% FDR)
kinase motifs (used “Motifs” column supplemental Table S3 which
was generated with Perseus software, based on Human Protein
Reference Database (31)) within the 83 up-regulated sites upon eto-
moxir treatment. The 83 sites were queried against the entire
phospho-dataset.
Computational Analysis Using Genome-Scale Metabolic Modeling—
Integration of Proteomics Data—Metabolic genes for which protein
abundance levels (LFQ) were measured in experiments were mapped
to the human genome-scale metabolic model (GSMM) (32). The mean
(over three replicas) of protein abundance levels in each time point
(i.e. 4 h, 22 h) were used to infer ternary presentation of the abun-
dance levels using “quartile” partitioning. This allowed for integrating
50% of the measured data, such that proteins in the top 25% quartile
were labeled “1” (highly abundant), proteins in the down 25% quartile
were labeled “1” (lowly abundant) and the rest were labeled “0”
(moderately abundant), in each time point. Based on the GSMM
gene-reaction rules, i.e. the logical dependence of each reaction on
the activity of the genes associated with it, we infer the ternary state
at the reaction level. This ternary representation was used as “cues”
(soft constraints) to perform iMAT (11) in each time point. To assess
the permissible flux range (i.e. minimal and maximal flux) of each
reaction we performed flux-variability analysis (FVA) around the opti-
mal solution that maximizes the agreement between the predicted
fluxes and the proteomic measurements. Then, we sampled the so-
lution space using ACHR algorithm and estimated the average flux of
each reaction. Fold changes between 22 h and 4 h were derived
based on the average fluxes.
The pathway enrichment analysis based on fold change reaction
flux between 4h and 22h matrigel (in supplemental Table S2) was
performed using the one dimension (1D) annotation enrichment anal-
ysis available in the Perseus software (33).
CPT1A Knockout Analysis—To simulate the effect of CPT1A inhi-
bition at 22h we simulated the metabolic state using iMAT twice: once
when the reactions associated with CPT1A were active at their max-
imal flux, and once when they were inhibited, carrying no flux. FVA
and sampling (ACHR) of the solution space were performed. Based
on the average fluxes of the reactions we estimated the fold change
following CPT1A inhibition as: fluxes when CPT1A was inactive/fluxes
when CPT1A was active.
Sample Preparation for Metabolomic Analysis—HUVECs were
seeded on a solidified matrigel (six well plate, 200 l/9.6 cm2) in
EGM-2 medium. After 3h, 22h, and 30h, cells were washed with PBS,
and medium replaced with 1 ml EGM-2, 11 mM 13C6 glucose and 100
M 12C16 palmitic acid or 11 mM
12C6 glucose and 100 M
13C16
palmitic acid. After 6h incubation at 37 °C metabolites were extracted
as follow from triplicate samples:
Extracellular—Twenty microliters of supernatant were mixed with
980 l of cold methanol/ACN/water (5:3:2 volumes) extraction buffer,
mixed (using a thermo-mixer) for 10 min at 4 °C, and spun 10 min at
16,100  g at 4 °C. Of the cleared supernatant, 800 l were stored at
80 °C until MS analysis.
Intracellular—cells were quickly washed with cold PBS and metab-
olites extracted upon incubation with 250 l of cold extraction
buffer for 5 min at 4 °C. Metabolites were then collected and mixed
FAO Maintains Endothelial Permeability
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(using a thermo-mixer) for 10 min at 4 °C and spun 10 min at 16,100
g at 4 °C. Of the cleared supernatant, 200 l were stored at 80 °C
until MS analysis.
Metabolomics MS Analysis—Metabolites were analyzed on an Ex-
active Orbitrap mass spectrometer (Thermo Fisher Scientific) coupled
online with a Accela HPLC system (Thermo Fisher Scientific). The
HPLC setup consisted of a ZIC-pHILIC column (150 2.1 mm, 5 m,
SeQuant, Merck KGaA), with a ZIC-pHILIC guard column (SeQuant,
20  2.1 mm) and an initial mobile phase of 20% 20 mM ammonium
carbonate, pH 9.4, and 80% acetonitrile. Of the metabolites extracted
from the cells and supernatant, 5 l were injected and separated over
a 30 min mobile phase gradient, decreasing the acetonitrile content to
20%, at a flow rate of 100 l/min. The total analysis time was 38 min.
All metabolites were detected across a mass range of 75–1000m/z at
a resolution of 25,000, at 200 m/z, with electrospray ionization and
polarity switching to enable both positive and negative ions to be
determined in the same run. Lock masses were used and the mass
accuracy obtained for all metabolites was below 5ppm. Data were
acquired with Xcalibur software.
Metabolomics Data Analysis—The peak areas ( measured inten-
sity) of different metabolites were determined using LCquan software
(Thermo Fisher Scientific) where metabolites were identified by the
exact mass of the singly charged ion and by known retention time on
the HPLC column. Commercial standards of all metabolites detected
had been analyzed previously on the same LC-MS system. The 13C
labeling patterns were determined by measuring peak areas for the
accurate mass of each isotopolog of many metabolites. The measure
intensities of the intracellular metabolites were normalized to the
amount of unlabeled intracellular arginine and phenylalanine.
SiRNA—For matrigel and Ca2 imaging experiments: the day be-
fore transfection, HUVECs were seeded in six-well plates at a con-
centration of 2  105 cells/well. Transfection of the siRNA duplexes
was performed with Oligofectamine according to the manufacturer’s
protocol (Invitrogen, Carlsbad, CA). Briefly, cells were transfected
with 360 pmol of nontargeting (Dharmacon-GE Healthcare) or lucifer-
ase-targeting siRNA as control, or pool or single Stealth Select RNAi
for CPT1A: SiCPT1A#1: CCACCAAGAUCUGGAUGGGUAUGGU;
SiCPT1A#2: GGACCGGGAGGAAAUCAAACCAAUU (Invitrogen). Af-
ter 48 h from transfection, cells were used for experiments. For the fibrin in
vitro angiogenesis assay and TEER, HUVECs were transfected using the
Amaxa Kit (Lonza) according to manufacturer’s instruction. After 48h from
transfection, cells were used for experiments.
Western blot Analysis—HUVECs were lysed in 2% SDS in 100 mM
Tris HCl, pH 7.4. Proteins were separated on NuPAGE 4–12% Bis-
Tris gel (Invitrogen) and transferred to PVDF membrane (Millipore).
The blots were probed with primary antibodies. Multi-color signals
were detected after incubation with secondary antibodies using
Odyssey CLx instrument (Li-COR Biosciences, Lincoln, NE). Sig-
nals were quantified using Image Studio lite software (LI-COR
Biosciences).
Cell Proliferation and Cell Death—Cell proliferation and cell death
were assessed using Click-iT EdU kit and Annexin V kit (Invitrogen)
according to manufacturer’s protocol. Briefly, HUVECs were seeded
at a concentration of 360 cells/mm2 in EGM-2 with the indicated
concentration of stimuli. After 20 h, cells were harvested (for EdU
incorporation, EdU was added 1.5–2 h before cell harvesting), stained
following manufacturer’s recommendations and analyzed at the
FACS or by immunofluorescence (siCPT1A experiment).
3D Fibrin Assay—Collagen-coated beads (Cytodex 3, Sigma-
Aldrich) were covered with HUVECs, embedded into fibrin gel as
previously described (34) and cultured for 2 days in EGM-2 medium in
the presence of the indicated stimuli.
Fatty Acid Oxidation Measurement—[1-14C] palmitic acid (Perkin
Elmer, Waltham, MA) or palmitic acid (Sigma) was resuspended in
-cyclodextrin (Sigma, 20 mg/ml in 10 mM Tris, pH 8) to obtain a 12
Ci/ml solution. HUVECs grown fully confluent in 35 mm dish were
incubated with the indicated stimuli for the indicated time and then
1.2 Ci/ml [1-14C] palmitic acid was added for 4h in the presence or
absence of stimuli. For the siRNA study, transfected HUVECs were
seeded the day before the assay then incubated with [1-14C] palmitic
acid for 4h. After 4h, the lids of the cell culture plates were covered
inside with Whatman paper and saturated with 5 M NaOH. Addition of
0.5 N perchloric acid triggered the release of CO2 that was captured
in the Whatman paper and analyzed in a scintillation counter (Micro-
Beta TriLux, Perkin Elmer). For the acid soluble metabolites, 1 ml of
medium was recovered, incubated with 200 l 4N KOH, 30 min at
60 °C to hydrolyze the acyl-CoA, esters and acidified with 300 l 1 M
NaC2H3O2 and 200 l 3N H2SO4. After spinning, 300 l of the super-
natant were mixed with 5 ml of a 2:1 solution of chloroform/methanol
to allow phase separation. The upper aqueous phase, where the acid
soluble metabolites (ASM) coming from palmitic acid oxidation are
dissolved, was incubated with scintillation fluid and analyzed in a
scintillation counter. The values obtained were normalized by cell
number.
Oxygen Consumption Rate Measurement—XF96 plates (Seahorse
Bioscience, North Billerica, MA) were coated with gelatin and 2.5 
104 HUVECs were seeded in EGM-2 medium. The day after, the
medium was replaced with unbuffered assay medium (Seahorse Bio-
science) with 0.5% FBS and 5 mM glucose, pH 7.4, and cells placed
at 37 °C in CO2-free incubator for 1 h. Basal oxygen-consumption
rate (OCR) was recorded using the XFe96 analyzer. Pyruvate and
dichloroacetate were added in subsequent injections. Each measure-
ment cycle consisted of 3 min mixing and 3 min measuring. At the end
of the experiment 1 M antimycin A was added in order to measure
mitochondria-independent oxygen consumption. Mitochondria-de-
pendent OCR is plotted.
ATP Assay—ATP was assessed using ATP determination kit (Invit-
rogen) according to manufacturer instruction. HUVECs were har-
vested and counted, then lysed in H2O (1 ml/1  10
6 cells) and boiled
for 10 min. After spinning, the supernatants were assessed with the
ATP determination kit, and luciferase activity was measured by Glo-
max luminometer (Promega, Madison, WI).
Calcium Imaging—Confluent HUVECs were grown in EGM-2 me-
dium on glass gelatin-coated coverslips for 4 days. Cells were next
loaded (45 min at 37 °C) with 2 M Fura-2 AM (Invitrogen), for ratio-
metric cytosolic Ca2 [Ca2]i measurements as previously described
(35). During the experiments cells were continuously bathed with a
microperfusion system. Fluorescence measurements were made us-
ing a Polychrome V spectrofluorometer (TILL Photonics, Munich
BioRegio, Germany) attached to a Nikon TE-2000-S (Nikon Corpora-
tion, Melville, NY) microscope and Metafluor Imaging System (Molec-
ular Devices, Sunnyvale, CA) for image acquisition using 3-s intervals.
During experiments, cells were maintained in standard extracellular
solution of the following composition: 145 mM NaCl, 5 mM KCl, 2 mM
CaCl2, 1 mM MgCl2, 10 mM N-(2-hydroxyethyl)-piperazine-N-ethane-
sufonic acid (HEPES), and 10 mM glucose (NaOH to pH 7.35). Cells
were continuously bathed with a microperfusion system. Each fluo-
rescence trace (340/380 nm ratio) represents one region of interest
(ROI) corresponding to cells in the chosen image field. Appropriate
controls were performed with vehicles (dH2O). Number of oscillations
was determined by IgorPro software (WaveMetrics Inc, Tigard, OR) by
multipeak fitting analysis function and expressed as number of oscil-
lation/10 min. The oscillation number is expressed as mean 	 S.E. of
at least three pooled experiments.
Permeability Assays—
In Vitro TEER—Cells were plated in EGM-2 on 12 mm gelatin-
coated transwell, 0.4 m pore size polyester membrane (Corning,
New York, NY), and grown tightly confluent. TEER was measured
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using a “chopstick” STX2 electrode connected to an EVOM2 volto-
hmmeter (World Precision Instruments, Sarasota, FL). TEER has been
measured also in wells without cells and values have been used as
background and subtracted to the values measured in the presence
of cells. The normalized values were used to calculate the % reported
in the figures.
In Vivo Ear Permeability—This assay was performed as previously
described with minor modifications (36). FVB/n wild type mice (The
Jackson Laboratory, Bar Harbor, ME) were pretreated with 4 mg/Kg
pyrilamine maleate salt (Sigma Aldrich) at least 30 min before Evans
blue injection, in order to block histamine release. Next, 100 l/mouse
of Evans blue (Sigma Aldrich) diluted 0.5% in saline solution was
intravenously injected. After two hours, mice were randomized and
subdivided into groups of four mice each. Different drugs were in-
jected intradermally with the following amounts: (1) 100 ng, 500 ng, 1
g, and 2 g of etomoxir; (2) 1 g, 2 g, 5 g, and 10 g of
oxfenicine; (3) 100 ng etomoxir combined with 500 ng pyruvate and 5
g dichloroacetate; (4) gadolinium 100 M was co-injected with 500
ng of etomoxir; and (5) saline solution was used as negative control.
Ten minutes after drug administration, the ears were excised and
photographed with a stereomicroscope connected to a camera by
means the Image ProPlus analyzer software. The amount of Evans
blue extravasation through the vessels was quantified with ImageJ
software. Mice were housed under the approval and the institutional
guidelines governing the care of laboratory mice of the University of
Torino Committee on Animal Research and in compliance with Na-
tional and International laws and policies.
Statistical Analysis—Unless indicated otherwise, bars represent
mean / Standard Error Mean (S.E.M.) (n3), p values have been
calculated using a two-tailed unpaired t test using GraphPad Prism
software. *p 
 0.05; **p 
 0.01; ***p 
 0.001;****p 
 0.0001.
The .raw MS files and search/identification files obtained with
MaxQuant have been deposited in the ProteomeXchange Consortium
(http://proteomecentral.proteomexchange.org/cgi/GetDataset) via the
PRIDE partner repository with the dataset identifier PXD001186.
RESULTS
ECs Remodel Their Metabolism upon Morphogenesis—To
identify metabolic pathways potentially involved in controlling
EC functions, we used iMAT to integrate time-resolved pro-
teomic data of human umbilical vein endothelial cells
(HUVECs, referred to as ECs throughout the Results section)
grown on matrigel with GSMM (Fig. 1A). ECs were used as
model because they are well-characterized primary endothe-
lial cells and relatively easy to isolate and culture. Using
high-resolution MS and label-free quantification algorithm
(14), we measured the proteome of ECs grown on matrigel for
4h (early matrigel) and 22h (late matrigel) (supplemental Table
S1), because at these time points cells have a distinct phe-
notype. At 4h cells are spread, proliferative and have started
forming a network, whereas at 22h cells are elongated, low
proliferative and have assembled into a fully formed complex
network (Fig. 1A, 1B). Proteomic changes between these two
time points pinpointed proteins involved in vessel maturation,
including increasing levels of cell–cell adhesion proteins ve-
cadherin (CDH5) and junction plakoglobin (JUP), the tyrosine
kinase receptor TIE1, and the endothelial nitric oxide synthase
(NOS3) [37, 38, 39](Fig. 1C). For each time point, 359 meta-
bolic enzymes (according to RECON (32), supplemental Table
S1) were quantified by MS of which 170 were defined as
highly or lowly abundant and used to build up a model that
predicts metabolic fluxes (supplemental Table S2). We rea-
soned that metabolic differences between 4h and 22h might
hint at pathways relevant for the regulation of EC functions.
Pathway enrichment analysis based on fold change reaction
flux between early and late matrigel highlighted FAO in per-
oxisome, the organelle where very-long-chain FAs can be
oxidized into short-chain FAs and released into the cytosol, as
the most up-regulated pathway when the network was fully
assembled, and TCAc as the most down-regulated (supple-
mental Table S2). Detailed investigation of single reaction flux
of FAs and glucose metabolism pinpointed increased trans-
port into the mitochondria of long-chain FAs, such as the
palmitoyl-CoA via CPT1 and CPT2, higher diffusion into the
mitochondria of short-chain FAs, such as the octanoyl-CoA
that can be generated by oxidation of very long fatty acids,
and increased flux of acyl-CoA dehydrogenases (ACADM and
ACADS)-catalyzed reactions of the FAO pathway (Fig. 1D,
1E). Conversely, decreased flux was predicted for reactions of
the glycolysis pathway catalyzed by hexokinase (HK), phos-
phofructokinase (PFK), aldolase (ALDO), and lactate dehydro-
genase (LDH), and for the pyruvate dehydrogenase (PDH),
which generates acetyl-CoA from pyruvate thus linking gly-
colysis to the TCAc (Fig. 1D, 1E). To verify our model, we
performed a MS stable isotope-based tracing metabolomic
analysis using 13C16-labeled palmitate and
13C6-labeled glu-
cose. This approach measures the metabolic activity of the
cells by calculating the amount of 13C-labeled palmitate and
glucose that cells convert into other metabolites. After early
time culture on matrigel, the 13C-labeled palmitoyl-carnitine,
whose formation is catalyzed by CPT1A from the 13C16-la-
beled-palmitate, was barely detected by MS while consis-
tently quantified when the network was fully formed after 22h
and 30h. Similar results were observed for the 13C-labeled
aspartate that is generated from TCAc intermediates (Fig. 1F
and supplemental Fig. S1A). Conversely, ECs in the fully
formed network decreased 13C-labeled glucose consumption
for glycolysis, as shown by more than 50% reduction of
13C-labeled secreted lactate and intermediates of glycolysis
and TCAc (Fig. 1G). To investigate whether the above meta-
bolic changes were specific for the matrigel system, and not
an effect of general cell adhesion mechanism or adaptation of
the cells to the cell culture, we used 14C-labeled palmitate and
measured FAO in ECs grown on culture dish for 4h and 22h.
In contrast to the results obtained in the matrigel assay, ECs
showed a significant reduction of FAO at 22h compared with
4h (supplemental Fig. S1B). Moreover, to assess that changes
in FAO were not just a reflection of the proliferative status of
the cells, we measured FAO in highly and low proliferative
cells (supplemental Fig. S1C). This showed that low prolifer-
ative ECs had lower FAO compared with highly proliferative
ones (supplemental Fig. S1D). These results demonstrate the
validity of our predictive metabolic model and indicate that,
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when assembled into a fully formed network, ECs enhance
FAO while reducing glycolysis.
CPT1A Inhibition Impairs EC Proliferation, Network Integ-
rity, and Sprouting—To investigate the functional role of FAO
in ECs, we first exploited the predictive metabolic model and
explored whether blocking FAO would alter metabolic fluxes.
To this aim, we inhibited CPT1A as it is the rate-limiting
enzyme in FAO and its levels were increased after 24h of ECs
culture on matrigel (Fig. 1H). By inactivating CPT1A in the
predictive metabolic model built up using the late matrigel
proteomic data, a substantial decrease in cellular ATP levels
was predicted (reactions 3789, 3791, and 3795 were among
the most down-regulated ones, supplemental Table S2).
These results suggest that FAO is a key factor in ECs and,
based on these observations, we further investigated the role
of FAO in ECs by targeting CPT1A. By inhibiting CPT1A either
pharmacologically with etomoxir, a well characterized drug
that targets CPT1 (40), or siRNA specific for CPT1A (supple-
mental Fig. S2A), FAO was substantially decreased (Fig. 2A,
2B). Because 15 g/ml etomoxir showed maximum FAO in-
hibition (Fig. 2A), we used this concentration for the following
experiments. A significant decrease in cell proliferation was
measured after 24 h treatment with etomoxir and when
CPT1A was silenced with siRNA, but not after 4 h etomoxir
treatment (Fig. 2C, 2D and supplemental Fig. S2B). These
changes had minor effects on cell death. Although no effects
were measured upon 24 h inhibition of CPT1A with etomoxir
(Fig. 2E), a small but significant increase in cell death (by
means of number of cells positive for both propidium iodide
and annexin V) was measured in cells where CPT1A was
silenced for 48h (Fig. 2F and supplemental Fig. S2C). Next we
tested the effects of CPT1A inhibition on EC morphogenesis.
When we grew ECs on matrigel for 24h in the presence of
etomoxir or when cells were silenced for CPT1A (supplemen-
tal Fig. S2D), a significant reduction (30–40%) of the network
integrity was measured (Fig. 2G, 2H and supplemental Fig.
S2E, 2F). To exclude that this effect was exclusively because of
a reduction in cell proliferation, we performed the matrigel assay
in the presence of mitomycin C, a DNA cross-linker that inhibits
cell proliferation (4) (supplemental Fig. S2G). This experiment
showed that etomoxir, but not mitomycin C treatment signifi-
cantly reduced network integrity (supplemental Fig. S2H). Sig-
nificant defects were also observed using a three-dimension
(3D) angiogenesis assay of ECs embedded into fibrin gel for 2
days. EC sprouting was significantly reduced in the presence of
etomoxir (Fig. 2I, 2J and supplemental Fig. S2I, 2J). Hence,
reduced CPT1A activity impairs key EC functions.
In ECs FAO Supports TCAc and ATP Production through
Oxidative Phosphorylation—FAO produces intermediates for
the TCAc, which is a central hub for energy production, and
our metabolic model predicted a sizable contribution of
CPT1A to maintain ATP levels. Therefore, we measured the
effects of CPT1A inhibition on cellular ATP levels. Because of
the limited number and accessibility of ECs when grown on
matrigel, to investigate the role of FAO in ECs, we performed
experiments using EC cultured in a monolayer. Acute (3h)
etomoxir treatment of ECs reduced total ATP levels of 10%
(Fig. 3A). This result is in line with the previous literature that
shows that 80% of ATP is derived from glycolysis and the
remaining from glucose, glutamine, and fatty acids oxidation
(4). When we replenished the TCAc of the etomoxir-treated
cells with dichloroacetate (DCA), a drug that activates the
pyruvate dehydrogenase A (PDHA1) by inhibiting the pyruvate
dehydrogenase kinase (Fig. 3B), and pyruvate, the substrate
that PDHA1 uses to generate acetyl-CoA, the ATP levels
were restored almost to the levels of control cells (Fig. 3A).
Consistently, inhibition of CPT1A induced a significant de-
crease in oxygen consumption rate (OCR) and OCR levels
raised with the replenishment of the TCAc with DCA and
pyruvate (Fig. 3C, 3D). Similar results were obtained upon
acute inhibition of FAO with oxfenicine, which is another
known inhibitor of CPT1 (10, 40) (supplemental Fig. S2K–M).
Fig. 1. ECs remodel their metabolism when assembled into a fully formed vascular network. A, Workflow showing the model used to
study EC morphogenesis, and how high-resolution proteomics has been integrated into the genome scale metabolic model using integrative
metabolic analysis tool (iMAT). B, HUVECs decrease proliferation when grown for 24 h on matrigel compared with 3h, assessed by EdU
incorporation ( % of cells in S phase of the cell cycle). C, Logarithmized LFQ intensity ratio (22 h/4 h) measured for the cell–cell junction
proteins ve-cadherin (CDH5) and plakoglobin (JUP), the tyrosine kinase receptor TIE1, and the endothelial nitric oxide synthase (NOS3), which
were found more abundant in HUVECs cultured on matrigel for 22 h compared with 4h. Bars represent mean of the LFQ intensity ratio 	 S.D.
(n  3) as reported in supplemental Table S1. D, Predicted flux changes upon morphogenesis for fatty acid oxidation (FAO) and glycolysis
reactions. x axis, enzymes that catalyze the reaction; HK, hexokinase; PFK, phosphofructokinase; ALDO, aldolase; LDH, lactate dehydroge-
nase; PDH, pyruvate dehydrogenase; CPT, carnitine O-palmitoyltransferase; ACADM/S, medium(M)/short(S)-chain specific acyl-CoA dehy-
drogenase, mitochondrial; Diff, diffusion octanoyl-CoA. E, Schematic representation of cell metabolism with highlighted the pathways in
D. OxPhos, oxidative phosphorylation. In brackets, reaction ID as in Supplemental Table S2. F, G, Tracing experiment where ECs were cultured
for 3h or 22h on matrigel followed by spike-in of 13C16-labeled palmitate, F, or
13C6 glucose, G, and 6h culture. Labeled (%), % of labeled
metabolite (peak area labeled) of the total amount (peak area labeled  peak area unlabeled). Peak area represents the amount of 13C-
labeled palmitoyl carnitine or lactate as measured by the mass spectrometer. For the palmitoyl carnitine the labeled (%) could not be measured
because the unlabeled palmitoyl-carnitine was not detected by MS. For the lactate, peak area representation allows evaluating the extent of
the glycolysis fuelled by extracellular 13C-labeled glucose.  Peak area  Extracellular palmitate uptake, which was measured as amount of
13C-labeled palmitate left in the medium at the end of the experiment minus the total amount of 13C-labeled palmitate that was initially
spiked-in. Bars  mean 	 S.D. (n  3). H, CPT1A levels (logarithmized LFQ intensity normalized by the average LFQ intensity measured at 4h)
in HUVECs cultured on matrigel for 4 h or 22 h. Bars  Mean 	 S.D. (n  6).
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Thus, CPT1A activity fuels TCAc and ATP production through
oxidative phosphorylation.
Phosphoproteomics Unveils That CPT1A Inhibition in ECs
Affects Calcium-Dependent Signaling—To further investigate
CPT1A functions, we used unbiased global phosphoproteo-
mics and assessed the impact of metabolic alterations in-
duced by acute CPT1A inhibition on EC signaling. Using a
triple-SILAC approach, we measured phosphoproteomic
changes after 2h etomoxir treatment and following replenish-
ment of the TCAc with pyruvate and DCA (Fig. 4A). In triplicate
experiments more than nine thousand accurately localized
(with a median localization probability (41) of 0.999) phospho-
rylation sites were quantified. Of those, 83, which belong to 62
proteins, increased phosphorylation levels upon etomoxir
treatment compared with nontreated control cells (supple-
mental Tables S3–S4). Based on Uniprot annotation, the reg-
ulated phosphoproteins included metabolic enzymes, ki-
nases, and proteins involved in the regulation of transcription,
translation, protein trafficking, and cytoskeleton. Additionally,
we exploited the phosphoproteomic data to look for kinases
responsible for the deregulated phospho-signaling. First we
evaluated that the phosphoproteomic changes were the re-
sults of altered kinase activity and not total protein levels. By
measuring the cell proteome to a depth of almost 5000 pro-
teins, only ten proteins increased levels upon etomoxir stim-
ulation and this subset did not include any of the proteins with
regulated phosphorylation sites (Fig. 4A and supplemental
Table S5). Thus, etomoxir-induced phosphorylations are
mostly the result of altered phospho-signaling. Next we used
NetworKIN (29), a platform that combines sequence specific-
ity, such as known linear kinase motifs surrounding the reg-
ulated phosphorylation site, and cellular context, such as
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FIG. 2. FAO regulates HUVEC functions. A, B, Reduced FAO upon etomoxir treatment (Eto, A) or CPT1A silencing with pool siRNA
(siCPT1A, B) in HUVECs, measured as 14C-labeled acid soluble metabolites produced from 14C-labeled palmitic acid. CCPM  corrected
count per minute. CCPM is expressed as percentage compared with the vehicle-treated cells (Ctl  100%); siCtl  nontargeting siRNA. C, D,
Cell proliferation upon etomoxir treatment for the indicated time, C, or CPT1A silencing (bars represent mean 	 S.D.) D, measured as
percentage of cells incorporating EdU. EdU cells are expressed as percentage compared with the control cells (Ctl  100%). E, F, Propidium
Iodide (PI) and annexin V (AV) staining of cells grown in the presence of etomoxir for 24 h, E, or silenced for CPT1A, F, was measured by FACS.
Starv, cells starved overnight in EBM-2. G, H, Reduced integrity of the network formed by cells after 24 h culture on matrigel in the presence
of etomoxir, G, or when silenced for CPT1A, H. I, J, Reduced sprouting in 3D-fibrin angiogenesis assay (48 h) performed with cells in the
presence of etomoxir, I, or silenced for CPT1A, J. p value according to Mann-Whitney test (n20 cell-coated beads).
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physical and functional protein–protein interactions, to iden-
tify the likely kinases responsible for the regulation of the 83
sites. This analysis predicted highest number of substrates
(12) for the calcium-calmodulin dependent kinase II (CamKII)
group (Fig. 4B, supplemental Table S6). Linear kinase motif
analysis with Motif-X strengthened this prediction and pin-
pointed the CamKII motif, which has an arginine in position
3 of the phosphorylated site (R--Sp), as significantly over-
represented among the 83 sites (Fig. 4C). Similarly, CamKII
was predicted active when performing a kinase motif (accord-
ing to known motifs in the HPRD database) enrichment anal-
ysis using the MaxQuant module Perseus (supplemental Fig.
S3A). This analysis further pinpointed highly significant en-
richment for the AMP-activated protein kinase (AMPK). AMPK
can be directly phosphorylated and activated by CamKII (17,
42), and NetworKIN predicted two AMPK substrates, of which
one is the known Ser80 of ACACA (43)(supplemental Fig.
S3B–D). We verified by Western blot analysis that ACACA in-
creases phosphorylation upon etomoxir treatment, and further
showed that in the presence of gadolinium (Gd3), which inhib-
its extracellular Ca2 entry (44), etomoxir-induced ACACA
phosphorylation was reduced (supplemental Fig. S3E). Finally,
detailed literature- and database-based investigation of the eto-
moxir-regulated phosphorylation sites pinpointed several sites
on proteins related to Ca2 signaling, such as the Ca2 sensor
STIM1 (45), the sodium/hydrogen exchanger SLC9A1, the adhe-
rens junction protein CTNNA1, the phosphatidylinositol transfer
protein PITPNM2, and the GTPase-activating protein ARGHAP17
(Fig. 4D). Of note, some of the sites decreased phosphorylation
levels upon pyruvate and DCA treatment (Fig. 4D).
All together, these data indicate that inhibition of FAO
with etomoxir activates Ca2/CamKII/AMPK pathway, and
suggest that CPT1A activity is required to maintain Ca2
homeostasis.
Acute CPT1A Inhibition Alters Calcium Homeostasis in ECs—
Measuring single-cell cytoplasmic Ca2 dynamics in ECs
showed that inhibition of CPT1A with etomoxir induced a
striking increase (threefold) of Ca2 oscillation frequency
within minutes (Fig. 5A, B). Notably, this alteration was fully
inhibited by blocking extracellular Ca2 entry with Gd3 or
replenishing the TCAc with pyruvate and DCA (Fig. 5B and
supplemental Fig. S4A). Demonstrating that etomoxir-in-
duced Ca2 oscillations were dependent on CPT1A inhibition,
ECs silenced for CPT1A did not increase Ca2 oscillations
frequency when treated with etomoxir (supplemental Fig.
S4B, S4C). Moreover, similar to etomoxir, ECs treated with
oxfenicine increased cytosolic Ca2 oscillations, and these
decreased by replenishing the TCAc (Fig. 5C, 5D). Together
these results demonstrate that in ECs CPT1A activity main-
tains Ca2 homeostasis.
CPT1A Inhibition Increases EC Permeability—Calcium is a
key regulator of endothelial permeability (46). Therefore, to
explore if the measured Ca2 alteration induced by inhibiting
CPT1A had an impact on EC functions, we measured the
permeability of an EC monolayer by means of trans-endothe-
lial electrical resistance (TEER), and compared it to known
inducers of hyperpermeability, thrombin and vascular endo-
thelial growth factor (VEGF). TEER of etomoxir-treated cells
showed a prominent decrease (30–40%) of resistance (
increase permeability) compared with control cells (Fig. 6A).
Similarly, increased permeability was measured in ECs upon
24 h treatment with etomoxir or when CPT1A was silenced
with siRNA (supplemental Figs. S2D and S4D, S4E). This
effect was around half of that induced by 1 unit/ml of thrombin
(60% decrease) and similar to 1 nM VEGF treatment (40%
decrease) (supplemental Fig. S4F, S4G). Confirming that the
above effect was driven by Ca2, ECs treated with Gd3 did
not increase permeability when treated with etomoxir (Fig.
A
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FIG. 3. FAO fuels the TCA cycle to generate energy. A, Decreased total cellular ATP levels induced by 3h etomoxir treatment increased
upon pyruvate and DCA treatment, as measured by luciferase activity. Luciferase activity is expressed as percentage compared with the
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Decreased phosphorylation levels of Ser293 and Ser300 (when phosphorylated by the pyruvate dehydrogenase kinase, PDHA1 activity is
inhibited), as measured by MS in the SILAC phosphoproteomic analysis of HUVECs treated with etomoxir (supplemental Table S3). The SILAC
ratio was calculated between cells treated with etomoxir and vehicle-treated cells (Ctl). A-C, represents three replicate experiments. C,
Seahorse measurements of oxygen consumption rate (OCR) show that etomoxir induces decrease OCR compared with control (Ctl) cells.
Replenishment of the TCAc with pyruvate and DCA increases OCR in both, Ctl and etomoxir-treated cells. Arrows indicate the measurements
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FIG. 4. Phosphoproteomics reveals
altered Ca2 signaling upon acute in-
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labeling conditions were swapped. B,
Predicted active kinases upon etomoxir
treatment (NetworKIN analysis). Num-
bers in brackets indicate the number of
predicted substrates shown in supple-
mental Table S6. C, Linear motif identi-
fied by Motif-X analysis. D, Etomoxir-up-
regulated phosphorylation sites on
proteins involved in Ca2 signaling (liter-
ature-based). Bars represent mean 	
S.D. (n2).
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6A). We further exploited the TEER assay to determine
whether replenishing the TCAc of etomoxir-treated ECs,
which we have shown to block aberrant Ca2 oscillations (Fig.
5A, 5B), would reduce hyperpermeability. Fig. 6B shows that
pyruvate and DCA treatment restored etomoxir-induced in-
creased permeability to the levels of control cells. Similar results
were obtained using blood outgrowth endothelial cells (BOECs),
another model of human primary endothelial cell that is derived
from peripheral blood (24, 47)(Fig. 6C), and when CPT1 activity
was inhibited with oxfenicine (Fig. 6D). Hence, impaired Ca2
homeostasis in CPT1-inhibited cells induces hyperpermeability.
Finally, we determined if the increased permeability was de-
pendent on the contribution of FAO to oxidative phosphoryla-
tion. To this aim, we used oligomycin, a drug that inhibits
oxidative phosphorylation by blocking the ATP synthase. Sim-
ilar to CPT1A inhibition, ECs treated with oligomycin had a
significantly reduced TEER. Moreover, oligomycin blocked the
recovery of the hyperpermeability induced by DCA and pyruvate
in etomoxir-treated ECs (Fig. 6E).
CPT1A Inhibition Increases Blood Vessel Leakage In
Vivo—To assess the relevance of our findings also in an in vivo
context, we investigated the effects of the acute inhibition of
CPT1A on vascular permeability. To this aim we used an
established Evans blue-based permeability assay of mature
blood vessels (36) and measured the leakage of blood vessels
in the mouse ear upon intradermal injection of vehicle, eto-
moxir or oxfenicine. We chose this system because it allows
minimizing indirect heart effects that can be induced by sys-
temic injection of the two drugs (40). Both etomoxir and
oxfenicine induced a dose-dependent increased leakage of
Evans blue (Fig. 7A, 7B and supplemental Fig. S5A, S5B).
Notably, the effects of etomoxir were significantly reduced
when co-injected with Gd3 and abrogated with pyruvate and
DCA (Fig. 7C–7F and supplemental Fig. S5C, S5D). Mirroring
the results observed in vitro, pharmacological inhibition of
CPT1A impairs vascular barrier function and this process is
dependent on Ca2 and TCAc activity (Fig. 7G).
DISCUSSION
In this work we built up the first predictive model of meta-
bolic fluxes based on high-resolution quantitative proteomic
data, which unveiled that HUVECs increase FAO and de-
crease glycolysis when assembled into a fully formed
network. Although it has been reported that loss of the rate-
limiting enzyme for glycolysis, PFKFB3, impairs EC prolifera-
tion and migration (4), so far there has been no evidence of
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endothelial functions altered by blockage of the FAO rate-
limiting enzyme CPT1A. By means of established drugs that
target CPT1A, gene silencing and global phosphoproteomics,
we demonstrate that FAO sustains oxidative phosphorylation
and maintains Ca2 homeostasis, and that this is required to
maintain adequate permeability of ECs in vitro and estab-
lished mouse blood vessels in vivo.
iMAT is a powerful computational tool to predict human
cellular metabolic fluxes integrating GSMM with gene expres-
sion data (11, 12); here we show that this analysis can be
successfully extended to the use of protein levels accurately
measured by MS-proteomics. We have validated some of the
predictions identified in our model, such as increased CPT1A
activity and decreased funneling of glucose into glycolysis in
HUVECs assembled into a fully formed network. Moreover,
we provide the full list of predicted metabolic reaction fluxes,
as resource of other metabolic processes potentially involved
in regulating EC behavior to be further investigated.
It has been previously shown that ECs preferentially use
glucose as energy source, have modest mitochondria con-
tent, and generate only a small amount of energy through
mitochondrial metabolism (4, 48). Accordingly, in our MS
metabolomic analysis we have identified only a limited subset
of metabolites generated from 13C-labeled palmitate. How-
ever, these were reliably quantified and led us to discover that
ECs increase FAO in conditions other than energetic stress
(7). Although future work is needed to address if changes
occurring when ECs are assembled into a fully-formed net-
work in vitro occur also during the maturation process of
newly formed blood vessels in vivo, our work demonstrates
that FAO plays a key role in ECs because acute and pro-
longed CPT1A inhibition impairs several cellular functions. To
identify the role of FAO in ECs, we focused on the effects of
acute pharmacological inhibition of CPT1A. This approach
allows dynamic manipulation and measurement of cell me-
tabolism and signaling, and identifies initial events that lead to
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the altered EC phenotypes upon prolonged CPT1A inhibition.
Of note, etomoxir and oxfenicine are used in clinics or pre-
clinical trials (10), thus extending the relevance of our study to
clinical context.
Phosphorylations are dynamic and reversible regulators of
protein functions and we reasoned that phosphoproteomics
would be excellent to investigate the signaling altered upon
short-time FAO inhibition and provide hints on the functional
role of CPT1A. This approach pinpointed alterations of the
Ca2/CamKII/AMPK pathway. Calcium is a master regulator
of cellular signaling and functions, and abnormal Ca2 homeo-
stasis can determine pathological states (49). In the vascular
context, Ca2 homeostasis is crucial to maintain the barrier
function of the blood vessels, and increased intracellular Ca2
levels in ECs increase cell permeability (46). For these rea-
sons, we focused our attention on Ca2 and demonstrate that
CPT1A activity maintains Ca2 homeostasis and EC perme-
ability. Furthermore, we show that this occurs through the
function of CPT1A to fuel TCAc and oxidative phosphorylation
(Fig. 7G). Thus, our work provides the first link between FAO
and Ca2 signaling. However, the detailed mechanism has
still to be elucidated. Intriguingly, mitochondria regulate Ca2
homeostasis by buffering cytosolic Ca2 (50) and ECs can
store up to 25% of the total cellular Ca2 in the mitochondria
(51). It is therefore tempting to hypothesize that the altered
mitochondrial activity (reduced ATP levels and OCR) induced
by FAO inhibition may affect the capability of the mitochondria
to buffer Ca2 and that this activates Ca2-signaling. Another
interesting question to be addressed in the future is if the
Ca2/CamKII/AMPK pathway is a functional driver of EC and
vascular hyperpermeability observed upon CPT1A inhibition.
In support of this hypothesis, it has been previously shown
that increased EC permeability in response to thrombin (52)
and VEGF (42) is induced through Ca2/CamKII/AMPK path-
way. Moreover, when we compared etomoxir- with thrombin-
driven phospho-signaling, which we have recently measured
using a similar MS-proteomic approach (24), we observed
that more than 50% of the phosphosites up-regulated by
etomoxir increased phosphorylation levels also upon throm-
bin stimulation (supplemental Table S3). These included pro-
teins involved in Ca2 signaling, such as STIM1 (45), SLC9A1,
and ACACA. Finally, our dataset is a potential resource for the
identification of other kinases (Fig. 4B) and detailed molecular
mechanisms (supplemental Table S3) that determine the phe-
notype of FAO-inhibited ECs.
In conclusion, our work highlights the power of using MS-
proteomics and metabolic modeling to better understand cell
metabolism and unravel its interplay with cell behavior. Here
we revealed a central role for CPT1A in ECs. Finally, our
results imply that inducing mitochondrial metabolism, includ-
ing FAO, for example using available drugs such as DCA,
could be a promising strategy to act directly on ECs and
counteract permeability defects observed in diseases such as
cancer, thrombosis and atherosclerosis, and trigger vascular
normalization. This study opens therefore new exciting per-
spectives for the study of FAO in ECs in pathophysiological
conditions.
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